Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28)

PLoS One. 2014 Feb 25;9(2):e89719. doi: 10.1371/journal.pone.0089719. eCollection 2014.

Abstract

Background: Oxidative stress plays an underlying pathophysiologic role in the development of diabetes complications. The aim of this study was to investigate peroxiredoxin 4 (Prx4), a proposed novel biomarker of oxidative stress, and its association with and capability as a biomarker in predicting (cardiovascular) mortality in type 2 diabetes mellitus.

Methods: Prx4 was assessed in baseline serum samples of 1161 type 2 diabetes patients. Cox proportional hazard models were used to evaluate the relationship between Prx4 and (cardiovascular) mortality. Risk prediction capabilities of Prx4 for (cardiovascular) mortality were assessed with Harrell's C statistic, the integrated discrimination improvement and net reclassification improvement.

Results: Mean age was 67 and the median diabetes duration was 4.0 years. After a median follow-up period of 5.8 years, 327 patients died; 137 cardiovascular deaths. Prx4 was associated with (cardiovascular) mortality. The Cox proportional hazard models added the variables: Prx4 (model 1); age and gender (model 2), and BMI, creatinine, smoking, diabetes duration, systolic blood pressure, cholesterol-HDL ratio, history of macrovascular complications, and albuminuria (model 3). Hazard ratios (HR) (95% CI) for cardiovascular mortality were 1.93 (1.57 - 2.38), 1.75 (1.39 - 2.20), and 1.63 (1.28 - 2.09) for models 1, 2 and 3, respectively. HR for all-cause mortality were 1.73 (1.50 - 1.99), 1.50 (1.29 - 1.75), and 1.44 (1.23 - 1.67) for models 1, 2 and 3, respectively. Addition of Prx4 to the traditional risk factors slightly improved risk prediction of (cardiovascular) mortality.

Conclusions: Prx4 is independently associated with (cardiovascular) mortality in type 2 diabetes patients. After addition of Prx4 to the traditional risk factors, there was a slightly improvement in risk prediction of (cardiovascular) mortality in this patient group.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood*
  • Cardiovascular Diseases / mortality*
  • Diabetes Mellitus, Type 2
  • Female
  • Humans
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Oxidative Stress*
  • Peroxiredoxins / blood*
  • Proportional Hazards Models
  • Risk Factors

Substances

  • Biomarkers
  • Peroxiredoxins

Grants and funding

This study was supported by grants of the Center of Excellence for Diabetes of the Isala Clinics, Zwolle, The Netherlands. S.J.L. Bakker received support from the Netherlands Heart Foundation, Dutch Diabetes Research Foundation and Dutch Kidney Foundation, together participating in the framework of the Center for Translational Molecular Medicine (CTMM) (www.ctmm.nl) project PREDICCt (grant 01C-104-07). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.